Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial

Jillian Johnson, Sheila N. Garland, Linda E. Carlson, Josée Savard, J. Steven A. Simpson, Sonia Ancoli-Israel, Tavis S. Campbell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue. Methods: This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life. Results: A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p =.034), wherein the BWL condition reported a 17% greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p’s < .01). Conclusions: BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes. Implications for cancer survivors: These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.

Original languageEnglish (US)
Pages (from-to)206-215
Number of pages10
JournalJournal of Cancer Survivorship
Volume12
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Phototherapy
Fatigue
Survivors
Randomized Controlled Trials
Neoplasms
Quality of Life
Depression
Light
Equipment and Supplies
Psychology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Oncology(nursing)

Cite this

Johnson, J., Garland, S. N., Carlson, L. E., Savard, J., Simpson, J. S. A., Ancoli-Israel, S., & Campbell, T. S. (2018). Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial. Journal of Cancer Survivorship, 12(2), 206-215. https://doi.org/10.1007/s11764-017-0659-3
Johnson, Jillian ; Garland, Sheila N. ; Carlson, Linda E. ; Savard, Josée ; Simpson, J. Steven A. ; Ancoli-Israel, Sonia ; Campbell, Tavis S. / Bright light therapy improves cancer-related fatigue in cancer survivors : a randomized controlled trial. In: Journal of Cancer Survivorship. 2018 ; Vol. 12, No. 2. pp. 206-215.
@article{3c0b4a5c2f1d4b1eafbb0276f5b47e6f,
title = "Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial",
abstract = "Purpose: Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue. Methods: This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life. Results: A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p =.034), wherein the BWL condition reported a 17{\%} greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p’s < .01). Conclusions: BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes. Implications for cancer survivors: These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.",
author = "Jillian Johnson and Garland, {Sheila N.} and Carlson, {Linda E.} and Jos{\'e}e Savard and Simpson, {J. Steven A.} and Sonia Ancoli-Israel and Campbell, {Tavis S.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s11764-017-0659-3",
language = "English (US)",
volume = "12",
pages = "206--215",
journal = "Journal of Cancer Survivorship",
issn = "1932-2259",
publisher = "Springer New York",
number = "2",

}

Johnson, J, Garland, SN, Carlson, LE, Savard, J, Simpson, JSA, Ancoli-Israel, S & Campbell, TS 2018, 'Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial', Journal of Cancer Survivorship, vol. 12, no. 2, pp. 206-215. https://doi.org/10.1007/s11764-017-0659-3

Bright light therapy improves cancer-related fatigue in cancer survivors : a randomized controlled trial. / Johnson, Jillian; Garland, Sheila N.; Carlson, Linda E.; Savard, Josée; Simpson, J. Steven A.; Ancoli-Israel, Sonia; Campbell, Tavis S.

In: Journal of Cancer Survivorship, Vol. 12, No. 2, 01.04.2018, p. 206-215.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bright light therapy improves cancer-related fatigue in cancer survivors

T2 - a randomized controlled trial

AU - Johnson, Jillian

AU - Garland, Sheila N.

AU - Carlson, Linda E.

AU - Savard, Josée

AU - Simpson, J. Steven A.

AU - Ancoli-Israel, Sonia

AU - Campbell, Tavis S.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose: Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue. Methods: This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life. Results: A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p =.034), wherein the BWL condition reported a 17% greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p’s < .01). Conclusions: BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes. Implications for cancer survivors: These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.

AB - Purpose: Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue. Methods: This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life. Results: A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p =.034), wherein the BWL condition reported a 17% greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p’s < .01). Conclusions: BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes. Implications for cancer survivors: These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=85033503039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033503039&partnerID=8YFLogxK

U2 - 10.1007/s11764-017-0659-3

DO - 10.1007/s11764-017-0659-3

M3 - Article

C2 - 29127575

AN - SCOPUS:85033503039

VL - 12

SP - 206

EP - 215

JO - Journal of Cancer Survivorship

JF - Journal of Cancer Survivorship

SN - 1932-2259

IS - 2

ER -